RE:RE:RE:RE:RE:RE:AstraZeneca's ADC disappoints - on severe adverse eventsAny Big Pharma company with an ADC has added interest in acquiring ONCY given pelareorep's ability to synergize the effectiveness of a checkpoint inhibitor in combination with the ADC. An Accelerated Approval in pancreatic cancer in combination with an immune checkpoint inhibitor sets the table for this combination to be combined with an ADC without significant further clinical testing, given that ONCY has already demonstrated effectiveness with chemotherapy plus immune checkpoint inhibitors.
Quentin30 and his like-minded operatives are those antagonists whose negative personas have repeatedly been identified for posting complete nonsense to try to shift the focus and course of narrative surrounding the positive developments surrounding ONCY.